Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PMSC-12
- Development stage
- Preclinical
- Lead developer
- Immorta Bio
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
PMSC-12 is an autologous cell therapy candidate being developed by Immorta Bio. It consists of Personalized Mesenchymal Stem Cells (pMSC) generated through the company's StemCell Revivify™ platform. The therapy is designed to restore youthful stem cell function and promote tissue repair. It is currently in preclinical development for the treatment of liver failure and as a potential intervention for systemic longevity.
- Other names
- Personalized Mesenchymal Stem CellspMSC
Beyond the preview
Go deeper on PMSC-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PMSC-12.